BioCentury
ARTICLE | Company News

Bristol-Myers Squibb, Apexigen deal

April 13, 2017 11:14 PM UTC

Apexigen will conduct a Phase I/II trial combining its APX005M with PD-1 inhibitor Opdivo nivolumab from Bristol-Myers. The trial will enroll second-line patients with metastatic non-small cell lung c...

BCIQ Target Profiles

CD40

PD-1